(1.08%) 5 072.76 points
(1.03%) 38 292 points
(1.63%) 15 860 points
(0.19%) $79.15
(5.59%) $2.04
(0.25%) $2 316.80
(0.66%) $26.93
(1.06%) $965.05
(-0.11%) $0.932
(-0.32%) $10.99
(-0.10%) $0.798
(-1.34%) $92.01
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 10.17%
@ $0.740
Išleistas: 13 vas. 2024 @ 19:37
Grąža: 1 643.65%
Ankstesnis signalas: vas. 13 - 18:13
Ankstesnis signalas:
Grąža: 0.58 %
Live Chart Being Loaded With Signals
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies...
Stats | |
---|---|
Šios dienos apimtis | 549 704 |
Vidutinė apimtis | 787 833 |
Rinkos kapitalizacija | 261.70M |
EPS | $0 ( 2024-03-14 ) |
Kita pelno data | ( $-3.10 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.930 |
ATR14 | $0.0370 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-05 | Hirsch Susan B | Buy | 5 000 | Stock Option |
2024-02-05 | Wiinberg Ulf | Buy | 5 000 | Stock Option |
2024-02-05 | Corvese Brian | Buy | 15 000 | Stock Option |
2024-02-05 | Jeynes-ellis Allison M | Buy | 5 000 | Stock Option |
2024-02-05 | Wright Timothy | Buy | 7 500 | Stock Option |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 11 279 188 | Sell: 367 647 |
Tūris Koreliacija
Agenus Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BTTX | 0.967 |
OMCL | 0.963 |
CDMO | 0.962 |
SCPH | 0.961 |
SVRE | 0.957 |
SILK | 0.957 |
OMER | 0.956 |
LIFE | 0.951 |
LITM | 0.951 |
CFRX | 0.951 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
FRSG | -0.974 |
IVCB | -0.973 |
TBSA | -0.97 |
LEGA | -0.968 |
CPAQ | -0.968 |
AHRN | -0.967 |
LGAC | -0.967 |
FTPA | -0.967 |
ACQR | -0.966 |
HORI | -0.966 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Agenus Inc Koreliacija - Valiuta/Žaliavos
Agenus Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $156.31M |
Bruto pelnas: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2023 |
Pajamos: | $156.31M |
Bruto pelnas: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2022 |
Pajamos: | $98.02M |
Bruto pelnas: | $-99.24M (-101.24 %) |
EPS: | $-0.960 |
FY | 2021 |
Pajamos: | $295.67M |
Bruto pelnas: | $113.59M (38.42 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.